Crash of Bayer stock shocks investors

The glyphosate lawsuit against Bayer subsidiary Monsanto is posing a risk to the pharmaceutical company's share price. Of course, one was aware of this issue when the company was bought last year. Nevertheless, the judgments seem to have a direct influence on the price of the securities even now. Just a judge has reduced the corresponding amount of damage - the general judgment but maintained. What impact does that have on the future performance of Bayer stock?